Literature DB >> 22249120

Lack of neurofibromatosis type 2 gene promoter methylation in sporadic vestibular schwannomas.

D Koutsimpelas1, G Ruerup, W J Mann, J Brieger.   

Abstract

BACKGROUND: Vestibular schwannomas (VS) are benign tumors of the nervous system that are usually sporadic but also occur in the inherited disorder neurofibromatosis type 2 (NF2). In VS, losses of chromosomal material and mutations of the NF2 gene have been established to be causative. For a subset of VS without detectable gene alterations, promoter inactivation by hypermethylation has been suggested. However, published data are very limited and contradictory.
METHODS: We analyzed NF2 gene promoter methylation in 35 sporadic VS by methylation-specific PCR.
RESULTS: Twenty-three of the tumors were informative, showing no promoter methylation. In the remaining 12 tumors, promoter methylation could neither be verified nor excluded.
CONCLUSIONS: Our study suggests that NF2 gene inactivation by promoter hypermethylation is a rare or very uncommon mechanism of NF2 gene inactivation in sporadic VS. Other mechanisms destabilizing the NF2 gene product, yet to be identified, might play a role in the genesis of VS apart from the loss or mutation of the NF2 gene.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22249120     DOI: 10.1159/000334968

Source DB:  PubMed          Journal:  ORL J Otorhinolaryngol Relat Spec        ISSN: 0301-1569            Impact factor:   1.538


  8 in total

Review 1.  Understanding the Molecular Mechanism of Vestibular Schwannoma for Hearing Preservation Surgery: Otologists' Perspective from Bedside to Bench.

Authors:  Makoto Hosoya; Takeshi Wakabayashi; Koichiro Wasano; Takanori Nishiyama; Nobuyoshi Tsuzuki; Naoki Oishi
Journal:  Diagnostics (Basel)       Date:  2022-04-21

Review 2.  [Pathogenesis and molecular pathology of vestibular schwannoma].

Authors:  M Brodhun; V Stahn; A Harder
Journal:  HNO       Date:  2017-05       Impact factor: 1.284

Review 3.  Role of Merlin/NF2 inactivation in tumor biology.

Authors:  A M Petrilli; C Fernández-Valle
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

4.  Global expression profile in low grade meningiomas and schwannomas shows upregulation of PDGFD, CDH1 and SLIT2 compared to their healthy tissue.

Authors:  Miguel Torres-Martin; Luis Lassaletta; Alberto Isla; Jose M De Campos; Giovanny R Pinto; Rommel R Burbano; Javier S Castresana; Barbara Melendez; Juan A Rey
Journal:  Oncol Rep       Date:  2014-10-03       Impact factor: 3.906

5.  Differential NF2 Gene Status in Sporadic Vestibular Schwannomas and its Prognostic Impact on Tumour Growth Patterns.

Authors:  Hongsai Chen; Lu Xue; Hantao Wang; Zhaoyan Wang; Hao Wu
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

6.  Global profiling in vestibular schwannomas shows critical deregulation of microRNAs and upregulation in those included in chromosomal region 14q32.

Authors:  Miguel Torres-Martin; Luis Lassaletta; Jose M de Campos; Alberto Isla; Javier Gavilan; Giovanny R Pinto; Rommel R Burbano; Farida Latif; Barbara Melendez; Javier S Castresana; Juan A Rey
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

7.  Microarray analysis of gene expression in vestibular schwannomas reveals SPP1/MET signaling pathway and androgen receptor deregulation.

Authors:  Miguel Torres-Martin; Luis Lassaletta; Jesus San-Roman-Montero; Jose M De Campos; Alberto Isla; Javier Gavilan; Barbara Melendez; Giovanny R Pinto; Rommel R Burbano; Javier S Castresana; Juan A Rey
Journal:  Int J Oncol       Date:  2013-01-24       Impact factor: 5.650

Review 8.  Genomics, Epigenetics, and Hearing Loss in Neurofibromatosis Type 2.

Authors:  Christine T Dinh; Eric Nisenbaum; Darius Chyou; Carly Misztal; Denise Yan; Rahul Mittal; Juan Young; Mustafa Tekin; Fred Telischi; Cristina Fernandez-Valle; Xue-Zhong Liu
Journal:  Otol Neurotol       Date:  2020-06       Impact factor: 2.619

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.